Anti-Mouse CD24 – Purified in vivo GOLD^TM Functional Grade

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

IHC^{29, 31},
IF^{29, 30},
IF Microscopy^29,
IP18

Anti-CD24 antibody (clone M1/69) activity is directed against mouse CD24, also known as Heat Stable Antigen (HSA) or Ly-52.

CD24 is expressed on B cells, T cells, neutrophils, eosinophils, macrophages, neural cells, ganglion cells, keratinocytes, muscle cells, pancreas cells, lymphocytes, granulocytes, epithelial cells, thymocytes, monocytes, erythrocytes, dendritic cells and is overexpressed in many cancers. Expression varies during T and B cell differentiation. Peripheral T cells are mainly negative.

Mouse CD24 is a small 27 amino acid sialoglycoprotein that is anchored to plasma membranes via a glycosyl-phosphatidylinositol linker¹. CD24 is widely distributed and plays a role in many diverse functions including adaptive immunity, inflammation, autoimmunity, and cancer^1,2. CD24 modulates growth and differentiation signals to granulocytes and B cells, is required for homeostatic cell renewal, binds to P-selectin on activated endothelial cells, plays a role in cell adhesion³, lymphocyte proliferation for homeostatic purposes⁴, lymphocyte costimulation via CD28-independent pathways⁵ as well as a crucial role in cell selection and maturation during hematopoiesis.

CD24 tends to be expressed more abundantly in progenitor cells and metabolically active cells relative to terminally differentiated cells². For example, CD24 is expressed on B-cell progenitors and mature resting B cells, but not terminally differentiated plasma cells. Similarly, CD24 is abundantly expressed on immature T cells and activated T cells but weakly expressed on peripheral T cells. As such, CD24 is used as a marker for the differentiation of hematopoietic and neuronal cells as well as tumor stem cells.

In humans, CD24 is overexpressed in various malignancies and its downregulation reduces cell tumorgenicity⁶. When CD24 is expressed early during carcinogenesis and blocked with monoclonal antibodies or small interfering RNA, tumor growth in xenograft mouse models is reduced.

M1/69 was generated by fusing the spleen cells of a DA rat immunized with B10 mouse spleen cells enriched for T cells with cells from a nonsecreting mouse myeloma line (NSI)⁷.

P-selectin, CD24

1. Kay R, Takei F, Humphries RK. J Immunol. 145:1952–1959. 1990.
2. Fang X, Zheng P, Tang J, et al. Cell Mol Immunol. 7(2):100-103. 2010.
3. Aigner S, Ruppert M, Hubbe M, et al. Int Immunol. 7:1557–1565. 1995.
4. Li O, Zheng P, Liu Y. J Exp Med. 200:1083–1089. 2004.
5. Hubbe M, Altevogt P. Eur J Immunol 24:731–737. 1994.
6. Sagiv E, Starr A, Rozovski U, et al. Cancer Res. 68(8):2803-2812. 2008.
7. Springer T, Galfrè G, Secher DS, et al. Eur J Immunol. 8(8):539-551. 1978.
8. Takei F, Secher DS, Milstein C, et al. Immunology. 42(3):371-378. 1981.
9. Gracz AD, Ramalingam S, Magness ST. Am J Physiol Gastrointest Liver Physiol. 298(5):G590-G600. 2010.
10. Shafer MER, Nguyen AHT, Tremblay M, et al. Stem Cell Reports. 8(4):1018-1031. 2017.
11. Shortman K, Wilson A, Egerton M, et al. Cell Immunol. 113(2):462-479. 1988.
12. Veillette A, Zúñiga-Pflücker JC, Bolen JB, et al. J Exp Med. 170(5):1671-1680. 1989.
13. Koni PA, Flavell RA. J Exp Med. 189(5):855-864. 1999.
14. Chappaz S, Flueck L, Farr AG, et al. Blood. 110(12):3862-3870. 2007.
15. Rucci F, Notarangelo LD, Fazeli A, et al. Proc Natl Acad Sci U S A. 107(7):3024-3029. 2010.
16. Teague TK, Tan C, Marino JH, et al. Int Immunol. 22(5):387-397. 2010.
17. Qiu Q, Ravens I, Seth S, et al. J Immunol. 184(4):1681-1689. 2010.
18. Young GR, Terry SN, Manganaro L, et al. J Virol. 92(1):e01507-17. 2017.
19. Gubin MM, Esaulova E, Ward JP, et al. Cell. 175(4):1014-1030.e19. 2018.
20. Evrard M, Kwok IWH, Chong SZ, et al. Immunity. 48(2):364-379.e8. 2018.
21. Schneppenheim J, Loock AC, Hüttl S, et al. J Immunol. 199(1):172-185. 2017.
22. Hoves S, Ooi CH, Wolter C, et al. J Exp Med. 215(3):859-876. 2018.
23. Lee JY, Kim J, Yi J, et al. Front Immunol. 9:437. 2018.
24. Fiege JK, Stone IA, Dumm RE, et al. PLoS Pathog. 15(9):e1008077. 2019.
25. Krovi SH, Kappler JW, Marrack P, et al. Proc Natl Acad Sci U S A. 116(44):22252-22261. 2019.
26. Wu W, Shi Y, Xia H, et al. Sci Rep. 7:44481. 2017.
27. Arkatkar T, Jacobs HM, Du SW, et al. Kidney Int. 94(4):728-740. 2018.
28. Chappel MS, Hough MR, Mittel A, et al. J Exp Med. 184(5):1639-1649. 1996.
29. Liu JQ, Carl JW Jr, Joshi PS, et al. J Immunol. 178(10):6227-6235. 2007.
30. Wagner G, Lindroos-Christensen J, Einwallner E, et al. Sci Rep. 7:40881. 2017.
31. Chen CY, Kimura H, Landek-Salgado MA, et al. Endocrinology. 150(1):492-499. 2009.